Study on the Blood Metabolome and Lipidomics Characteristics of Atopic Dermatitis/Alopecia Areata Patients Before and After JAK Inhibition Treatment

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500096551

Enrollment

Unknown

Registered

2025-01-26

Start date

2025-03-01

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis Alopecia areata

Interventions

atopic dermatitis:jak inhibitor

alopecia areata:jak inhibitor

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.AD or alopecia areata patients aged between 18 and 60 years old; 2.Meet the clinical diagnostic criteria for AD or alopecia areata; 3.No other serious chronic diseases; 4.Not using drugs such as JAK inhibitors that affect metabolism in the past 3 months; 5.After clinical evaluation, it is deemed necessary to receive JAK inhibitor treatment (not limited to brands);

Exclusion criteria

Exclusion criteria: 1.Pregnant and lactating women; 2.Individuals with severe liver and kidney dysfunction; 3.Have a history of metabolic diseases (such as diabetes); 4.Individuals allergic to JAK inhibitors;

Design outcomes

Primary

Measure	Time frame
Metabolome;Lipid group;	—

Countries

China

Contacts

Public ContactRong Xiao

Second Xiangya Hospital of CSU

xiaorong65@aliyun.com+86 731 85295260

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026